Purification of breast cancer resistance protein ABCG2 and role of arginine-482.
Human ABCG2 was efficiently overexpressed in insect cell membranes, solubilized with 3-[(3-cholamidopropyl)dimethyl ammonio]-1-propanesulfonate, and purified through N-terminal hexahistidine tag. Its functionality was assessed by high vanadate-sensitive ATPase activity, and nucleotide-binding capacity. Interestingly, the R482T point mutation increased both maximal hydrolysis rate and affinity for MgATP, and lowered sensitivity to vanadate inhibition. Direct nucleotide binding, as monitored by quenching of intrinsic fluorescence, indicated a mutation-related preference for ATP over ADP. The R482T mutation only produced a limited change, if any, on the binding of drug substrates, indicating that methotrexate, on the one hand, and rhodamine 123 or doxorubicin, on the other hand, bound similarly to wild-type and mutant transporters whether or not they were subject to cellular transport. In addition, the characteristic inhibitors GF120918 and 6-prenylchrysin, which alter mitoxantrone efflux much better for wild-type than mutant ABCG2, bound similarly to purified ABCG2, while the highly-potent Ko143 bound in the nanomolar range also effective in inhibition of drug transport. All results indicate that the role of the arginine-482 mutation on substrate drug transport and inhibitor efficiency is not mediated by changes in drug binding.
Pozza
A
A
Institut de Biologie et Chimie des Protéines, UMR5086 CNRS-Université de Lyon et IFR128 BioSciences Lyon-Gerland, 7 Passage du Vercors, 69367, Lyon Cedex 07, France.
Perez-Victoria
J M
JM
Sardo
A
A
Ahmed-Belkacem
A
A
Di Pietro
A
A
D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D000244:Adenosine Diphosphate / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D019943:Amino Acid Substitution; D000911:Antibodies, Monoclonal; D001943:Breast Neoplasms / Q000473:pathology / Q000503:physiopathology*; D002462:Cell Membrane / Q000502:physiology / Q000648:ultrastructure; D003001:Cloning, Molecular; D017931:DNA Primers; D018432:Drug Resistance, Multiple; D005260:Female; D006801:Humans; D007700:Kinetics; D008942:Mitoxantrone / Q000493:pharmacokinetics; D016297:Mutagenesis, Site-Directed; D009363:Neoplasm Proteins / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D011994:Recombinant Proteins / Q000302:isolation & purification / Q000378:metabolism; D014638:Vanadates / Q000378:metabolism
C116614:ABCG2 protein, human; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; D000911:Antibodies, Monoclonal; D017931:DNA Primers; D009363:Neoplasm Proteins; D011994:Recombinant Proteins; D014638:Vanadates; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D008942:Mitoxantrone